TY - JOUR T1 - Fatigue in newly diagnosed acute myeloid leukaemia: general population comparison and predictive factors JF - BMJ Supportive & Palliative Care JO - BMJ Support Palliat Care DO - 10.1136/bmjspcare-2020-002312 SP - bmjspcare-2020-002312 AU - Laura B Oswald AU - Adriano Venditti AU - David Cella AU - Francesco Cottone AU - Anna Candoni AU - Lorella Melillo AU - Roberto Cairoli AU - Gabriella Storti AU - Prassede Salutari AU - Mario Luppi AU - Francesco Albano AU - Maria Paola Martelli AU - Antonio Cuneo AU - Agostino Tafuri AU - Silvia Maria Trisolini AU - Alessia Tieghi AU - Paola Fazi AU - Marco Vignetti AU - Fabio Efficace Y1 - 2021/05/03 UR - http://spcare.bmj.com/content/early/2021/05/03/bmjspcare-2020-002312.abstract N2 - Objectives This study compared the burden of fatigue between treatment-naïve patients with newly diagnosed acute myeloid leukaemia (AML) and the general population and investigated patient factors associated with fatigue severity.Methods Pretreatment patient-reported fatigue was assessed with the Functional Assessment of Chronic Illness Therapy-Fatigue questionnaire in a sample of 463 newly diagnosed patients with AML who were enrolled in a clinical trial. Multivariable linear regression models were used to estimate the adjusted mean differences in fatigue between patients with AML and adults from the general population (n=847) by AML disease risk categories. A clinically meaningful difference in fatigue was defined as ≥3 points. Univariable and multivariable linear regression models were used to identify sociodemographic, clinical and molecular correlates of worse fatigue in patients with AML.Results Patients with AML reported adjusted mean fatigue scores that were 7.5 points worse than the general population (95% CI −8.6 to −6.4, p<0.001). Across AML disease risk categories, adjusted mean differences in fatigue compared with the general population ranged from 6.7 points worse (patients with favourable risk: 95% CI −8.6 to −4.8, p<0.001) to 8.9 points worse (patients with poor risk, 95% CI −10.5 to −7.2, p<0.001). Overall, 91% of patients with AML reported fatigue that was equal to or worse than the general population’s median fatigue score. Higher pretreatment fatigue was independently associated with female sex, WHO performance status ≥1 and lower platelet levels.Conclusions Patients with newly diagnosed AML reported worse fatigue than the general population, and mean differences exceeded twice the threshold for clinical significance. Our findings may help to identify patients with AML most likely to benefit from supportive care interventions to reduce fatigue.Data are available upon reasonable request. ER -